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Background: Gonorrhoea and widely spread antimicrobial resistance (AMR) in its etiological agent Neisseria
gonorrhoeae are major public health concerns worldwide. Gonococcal AMR surveillance nationally and
internationally, to identify emerging resistance and inform treatment guidelines, is imperative for public health
purposes. In 2009, AMR surveillance was initiated in Belarus, Eastern Europe because no gonococcal AMR data had
been available for at least two decades. Herein, the prevalence and trends of gonococcal AMR and molecular
epidemiological characteristics of N. gonorrhoeae strains from 2010 to 2013 in Belarus, are described.
Methods: N. gonorrhoeae isolates (n=193) obtained in the Mogilev (n=142), Minsk (n=36) and Vitebsk (n=15)
regions of Belarus in 2010 (n=72), 2011 (n=6), 2012 (n=75) and 2013 (n=40) were analyzed in regards to AMR using
the Etest method and for molecular epidemiology with N. gonorrhoeae multi-antigen sequence typing (NG-MAST).
Results: During 2010–2013, the proportions of resistant N. gonorrhoeae isolates were as follows: tetracycline 36%,
ciprofloxacin 28%, penicillin G 9%, azithromycin 5%, and cefixime 0.5%. Only one (0.5%) β-lactamase producing
isolate was detected. No isolates resistant to ceftriaxone and spectinomycin were identified. Overall, the resistance
levels to tetracycline, ciprofloxacin and penicillin G were relatively stable. Interestingly, the level of resistance to
azithromycin declined from 12% in 2010 to 0% in 2013 (P < 0.05). In total, 70 NG-MAST STs were identified. The
predominant STs were ST1993 (n=53), ST807 (n=13), ST285 (n=8) and ST9735 (n=8). Many novel STs (n=43, 61%),
representing 41% of all isolates, were found.
Conclusions: During 2010–2013, the N. gonorrhoeae population in Belarus displayed high and relatively stable
resistance levels to tetracycline, ciprofloxacin, and penicillin G, while the resistance to azithromycin declined. One
isolate was resistant to cefixime, but no resistance to ceftriaxone or spectinomycin was found. The results of the
present surveillance initiated in 2009 were also used to replace penicillin G with ceftriaxone (1 g single dose
intramuscularly) as the first-line drug for empiric treatment of gonorrhoea in the national treatment guidelines in
Belarus in late 2009. It is essential to further strengthen the surveillance of gonococcal AMR and ideally survey also
treatment failures and molecular epidemiological genotypes in Belarus.
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Gonorrhoea, etiological agent Neisseria gonorrhoeae, is a
public health concern globally. In most of the non-
European Union (EU)/European Economic Area (EEA)
countries (n=23), which mostly represent independent
countries from the former Soviet Union and Yugoslavic
Republic, of the World Health Organization (WHO)
European Region (53 countries), the gonorrhoea incidence
has rapidly declined during the last 20 years. In the Eastern
European non-EU/EEA country Belarus (9.5 million inhabi-
tants), the incidence has also mainly declined during the
last two decades. However, the incidence remains high and
in 2011 Belarus reported the third highest incidence (35.4
per 100 000 population) in the WHO European Region
([1,2],http://data.euro.who.int/cisid). The reported gonor-
rhoea incidences in Belarus might also be underestimated,
which is due to suboptimal diagnostics, access to testing,
case reporting, e.g. lack of reporting of cases diagnosed in
the private sector, and surveillance [2-4].
N. gonorrhoeae has developed antimicrobial resistance
(AMR) to all drugs previously recommended for treat-
ment of gonorrhoea. In vitro (low-level and high-level)
and rare treatment failures have now emerged to the last
remaining option for first-line empirical monotherapy in
most countries globally, that is, the extended-spectrum
cephalosporin (ESC) ceftriaxone [5-18]. Therefore, en-
hanced and quality assured surveillance of gonococcal
AMR, nationally and internationally, is essential to moni-
tor the AMR trends, identify emerging AMR and inform a
regular update of the STI management and treatment
guidelines locally, nationally and globally. This is in strict
concordance with the global action plan and European
response plan to combat gonococcal AMR published by
the WHO [19,20] and the European Centre for Disease
Prevention and Control (ECDC) [21], respectively.
Worryingly, in the non-EU/EEA countries of the WHO
European Region, quality assured gonococcal AMR surveil-
lance only exist in 13% (3/23) of the countries [2]. In 2009,
because no gonococcal AMR data had been available for at
least two decades gonococcal AMR surveillance was initiated
in Belarus by the Eastern European Network for Sexual and
Reproductive Health [22] in collaboration with the WHO.
This AMR surveillance has been quality assured in accord-
ance with WHO standards and the 2008 WHO N. gonor-
rhoeae reference strains are used as quality controls [23].
The aims of the present study were to describe the
prevalence and trends of gonococcal AMR and molecular
epidemiological characteristics of N. gonorrhoeae strains
from 2010 to 2013 in Belarus.
Methods
Study population
N. gonorrhoeae isolates (n=193) were obtained at the
Mogilev Regional (n=142), Minsk City (n=36) andVitebsk Regional (n=15) Dermato-Venerological Dis-
pensaries in Belarus in 2010 (n=72), 2011 (n=6), 2012
(n=75) and 2013 (n=40). Mainly consecutive culture
positive gonorrhoea patients from January 2010 to April
2013 were included. Urethral and cervical specimens
from females and urethral specimens from males were
collected.
All specimens were cultured on selective gonococcal
agar media and suspected gonococcal colonies were
subsequently confirmed as N. gonorrhoeae by colony
morphology, Gram staining, oxidase test and a carbohy-
drate utilization test [24]. The isolates were stored in
cryogenic storage dewar with liquid nitrogen (−196°C)
or in ultra-low temperature freezer (−70°C) in preserva-
tion media and then shipped on dry ice to the WHO
Collaborating Centre for Gonorrhoea and other STIs,
Sweden for further analysis. All examined gonococcal
isolates were cultured and stored as part of the routine
diagnostics (standard care) and no patient identification
information was available in the study.
Antimicrobial susceptibility and β-lactamase testing
The minimum inhibitory concentration (MIC; mg/L) of
ceftriaxone, cefixime, azithromycin, spectinomycin, cip-
rofloxacin, penicillin G, tetracycline and gentamicin was
analysed using the Etest methodology on Difco GC
Medium Base (Becton, Dickinson and Company, Sparks,
MD, USA) supplemented with 1% BBL IsoVitaleX
Enrichment (Becton, Dickinson and Company, Sparks,
MD, USA), with agar plates incubated for 18–20 h at
35-37°C in a 5% CO2-enriched atmosphere, according to
the instructions from the manufacturer (bioMérieux AB,
Solna, Sweden). The Etest results were interpreted as
susceptible (S), intermediate susceptible (I) and resistant
(R) according to the breakpoints stated by The European
Committee on Antimicrobial Susceptibility Testing
(EUCAST; www.eucast.org/clinical_breakpoints). For gen-
tamicin, no breakpoints are stated by any organization
and, accordingly, only MIC range, MIC50 and MIC90 were
used.
β-lactamase production was identified with nitrocefin
solution (0.5 g/mL), according to the manufacturer’s
instructions (Oxoid, Basingstoke, Hants, England).
Isolation of genomic DNA
Genomic DNA was isolated using the NorDiag Bullet
robot (NorDiag ASA Company, Oslo, Norway) with
BUGS’n BEADS STI-fast kit (NorDiag ASA Company,
Oslo, Norway), according to the manufacturer’s instructions.
Molecular epidemiological typing
NG-MAST [25,26] was performed as previously described
[27]. NG-MAST allele numbers of the more variable
segments of porB and tbpB, and sequence types (STs) were
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Statistical analysis
Statistical analysis was performed using the Statistica
software version 9.0. Z-test for comparison of proportions
was used. The level of significance was set at P < 0.05.
Results
Patient characteristics
N. gonorrhoeae isolates (one isolate per patient) from
193 patients; 169 (87.6%) males and 24 (12.4%) females,
were examined. The mean age for the males was 26.9 years
(median age: 25.0 years; range: 19 to 57 years) and for the
females 27.3 years (median age: 28.5 years; range: 19 to
33 years). The male/female ratio and age distribution was
relatively similar during the four years investigated.
Antimicrobial susceptibility of N. gonorrhoeae isolates in
2010–2013 (n=193) in Belarus
The overall antimicrobial susceptibility of all isolates is
summarized in Table 1.
Briefly, the levels of in vitro resistance during 2010–
2013 were as follows: tetracycline 36%, ciprofloxacin 28%,Table 1 Antimicrobial susceptibility of Neisseria gonorrhoeae
Antimicrobial MIC50/ Susceptible (%) Interme
MIC90/ 2010-2011 2012 2013 2010-20
MIC range (n=78) a (n=75) (n=40) (n=78) a
(mg/L)
Penicillin Gb 0.032/1/ - 88 78 -
0.008-2
Ceftriaxoneb 0.008/0.047/ 100 100 100 NA
<0.002-0.125
Cefiximeb 0.023/0.047/ 100 100 97.5 NA
<0.016-0.25
Azithromycinb 0.19/0.38/ 65 83.3 90 23
0.032-1
Ciprofloxacinb 0.006/6/ 64 79 72 1
0.003- >32
Tetracyclineb 0.38/24/ 56 56 55 8
0.094-24
Spectinomycinb 12/16/3-16 100 100 100 NA
Gentamicinc 2010-2011: 2012:




MIC50, minimum inhibitory concentration of 50% of isolates; MIC90, minimum inhibi
aDue to the few isolates obtained in 2011, isolates from 2010 (n=72) and 2011 (n=6
bBreakpoints for susceptible and resistant isolates were according to the European
(EUCAST; www.eucast.org/clinical_breakpoints).
cBreakpoints not stated by any organization.penicillin G 9%, azithromycin 5%, and cefixime 0.5% (one
isolates with an MIC of 0.25 mg/L). Only one (0.5%)
β-lactamase producing isolate was found. No isolates
resistant to ceftriaxone and spectinomycin were iden-
tified. Overall, the resistance levels to tetracycline,
ciprofloxacin and penicillin G were relatively stable.
Interestingly, the level of resistance to azithromycin
significantly declined from 12% in 2010 to 0% in
2013 (P < 0.05). For gentamicin (MIC range: 0.25-
16 mg/L), the MICs were relatively low and all isolates
considered susceptible (Table 1).
The proportion of isolates with ceftriaxone MIC <
0.002 mg/L was 44%, 67%, and 63% in 2010/2011, 2012
and 2013, respectively, and in general the annual MIC
distribution for ceftriaxone appeared to shift to lower
MICs during the study period 2010–2013 (Figure 1).
However, although no resistance to ceftriaxone was
identified, in total 3.1% (5% in 2013) had a ceftriaxone
MIC of 0.125 mg/L, which is exactly at the resistance
breakpoint stated by the EUCAST (www.eucast.org/
clinical_breakpoints). Gonococcal isolates with these
MICs have previously resulted in ceftriaxone treatment
failures and can be considered to have a decreased
susceptibility [12-14,16-18].isolates (n=193) from Belarus, 2010–2013
diate susceptible (%) Resistant (%)
11 2012 2013 2010-2011 2012 2013
(n=75) (n=40) (n=78) a (n=75) (n=40)
5 10 - 7 13
NA NA 0 0 0
NA NA 0 0 2.5
15.3 10 12 1.3 0
0 0 35 21 28
9 5 36 35 40
NA NA 0 0 0
2013:
e: 2-16 mg/L; MIC50: 4 mg/L;
mg/L
MIC range: 3-12 mg/L; MIC50: 6 mg/L;
MIC90: 8 mg/L
tory concentration of 90% of isolates; −, Not tested; NA, not applicable.
) were evaluated as one time point.
Committee on Antimicrobial Susceptibility Testing
Figure 1 The distribution of minimum inhibitory concentrations (MICs) of ceftriaxone for Neisseria gonorrhoeae isolates (n=193)
cultured in Belarus from 2010 to 2013.
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The 193 were assigned to 70 different NG-MAST STs.
The most prevalent ST was ST1993 (n=53, 27.5% of
isolates), followed by ST807 (n=13, 6.7%), ST285 (n=8,
4.1%), ST9735 (n=8, 4.1%) and ST2873 (n=6, 3.1%). The
remaining STs were represented by five (1 cluster), four
(n=3), three (n=8), two (n=11) and one (n=42) isolates.
Forty-three (61%) of these STs were not previously
described. In general, the most prevalent STs such as
ST1993, ST807, ST285 and ST9735 had relatively low
MICs of ceftriaxone. Notably, the cefixime resistant
gonococcal isolate obtained in 2013 was assigned as
ST3149.
Discussion
In the present study, the AMR in N. gonorrhoeae isolates
cultured from 2010 to 2013, and molecular epidemio-
logical characteristics (NG-MAST) of N. gonorrhoeae
isolates in Belarus were examined. Previously, only one
minor AMR study examining gonococcal isolates from
Belarus in 2009 [28] has been internationally published.
Accordingly, exceedingly limited phenotypic and genetic
characteristics of the gonococcal strains spreading in
Belarus have been previously published.
High prevalences of resistance were observed for pre-
viously recommended antimicrobials such as tetracycline
(36%), ciprofloxacin (28%), and penicillin G (9%). In
accordance with the WHO recommendations regarding
exclusion of an antimicrobial when the resistance level
reaches ≥5% in the general population, none of these an-
timicrobials should be recommended for empirical first-
line monotherapy of gonorrhoea in Belarus or in most
other countries globally where resistance is prevalent
[2,5-11]. In line with this, the results of the presentsurveillance initiated in 2009 [28] were also used to re-
place penicillin G with ceftriaxone as the first-line drug
for empiric treatment of gonorrhoea in the national
treatment guidelines in Belarus in late 2009 [29]. Inter-
estingly, β-lactamase producing gonococcal strains ap-
pear to be exceedingly rare (1/193 isolates) in Belarus,
which is also the case in some other independent coun-
tries of the former Soviet Union such as Russia [30-33].
In Belarus, where penicillin G and other penicillin deriv-
atives have been widely used for treatment of gonor-
rhoea at least until 2010, this may indicate that no
imported β-lactamase producing gonococcal strains have
been established and resulted in an endemic spread in
Belarus. Resistance to azithromycin was also relatively
prevalent (5%), however, no isolates with high-level re-
sistance to azithromycin (MIC ≥ 256 mg/L), which have
been described from several other countries [34-39],
have yet been identified in Belarus. Furthermore, the re-
sistance to azithromycin significantly declined from 12%
in 2010 to 0% in 2013, which might reflect that azithro-
mycin is rarely used for treatment of gonorrhoea and
utilized in a controlled manner in the treatment of other
STIs such chlamydial infection.
Since late 2009, in Belarus ceftriaxone 1 g single dose
intramuscularly is the nationally recommended first-line
treatment for uncomplicated anogenital and extra-
genital gonorrhoea [29]. In the present study, no ceftri-
axone resistant isolates and only one (0.5%) cefixime re-
sistant isolate were identified. This is in contrast to the
findings in the neighbouring country Russia, where
according to the EUCAST breakpoints (www.eucast.org)
2.7% of isolates were resistant to ceftriaxone in 2009–
2012 [33]. The reasons for the low MICs of ceftriaxone
in Belarus are unknown. However, this might reflect that
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sistance to ESCs has been imported and/or managed to
establish any domestic spread. Furthermore, in Belarus
cefixime or other less potent oral ESCs have never been
widely used for treatment of gonorrhoea. No resistance
to spectinomycin was either found. This is also in con-
trast to the findings in Russia, where isolates with low-
level resistance to spectinomycin are detected every year
[31-33]. Worryingly, in Belarus despite that ceftriaxone
1 g single dose intramuscularly is the recommended
first-line regimen penicillins, fluoroquinolones, macro-
lides, and other cephalosporins remain to be used in the
routine gonorrhoea treatment. Furthermore, antimicro-
bials are easily available “over-the-counter”, and this
practice is crucial to abandon. The use of also less
potent antimicrobials in the treatment of gonorrhoea,
spread of gonococcal strains with decreased ESC suscep-
tibility in Belarus and ESC resistance internationally,
including in the neighbouring country Russia where also
spectinomycin resistance are spreading, necessitate an
enhanced surveillance of gonococcal AMR (with focus
on ceftriaxone but also multidrug resistance), and ideally
also treatment failures and molecular epidemiological
characteristics in Belarus. There are also initiatives to
improve the gonococcal AMR surveillance in Belarus,
that is, to increase the number of isolates examined an-
nually, the geographic representativeness by including
additional regions, and the linkage to appropriate epi-
demiological data. In general, national and international
support, including political and financial commitment,
is essential to strengthen the gonococcal AMR surveil-
lance in non-EU/EEA countries of the WHO European
Region [2-4].
NG-MAST has been used in many countries world-
wide; to monitor the national and international spread
of gonococcal strains, including AMR clones, to iden-
tify transmission patterns within sexual networks, and
to verify or falsify suspected treatment failures [26]. In
Belarus, during 2010–2013 70 different NG-MAST
STs among 193 isolates were identified. The substan-
tial number of STs represented by only one isolate
(n=42) and STs that have not been previously de-
scribed (n=43; 61%) may be associated with the low
number of cultured gonococcal isolates from each sur-
veillance site, suboptimal diagnostics, lack of tracing
of sexual contacts, and STs evolved locally in Belarus.
Nevertheless, some major ST clusters of, e.g., ST1993
(n=53, 27.5% of isolates), followed by ST807 (n=13,
6.7%), ST285 (n=8, 4.1%), and ST9735 (n=8, 4.1%),
were identified, which indicate some larger sexual
transmission chains. No isolates assigned as ST1407,
the internationally spread multidrug resistant gono-
coccal clone [5,8,11,14,18,40-44], was identified from
2010 to 2013 in Belarus.Conclusions
In Belarus, during 2010–2013 the heterogeneous gono-
coccal population showed high and relatively stable
resistance levels to ciprofloxacin, tetracycline and peni-
cillin G. The overall resistance to azithromycin was also
relatively high, however, significantly declined from 2010
to 2013. One isolate was resistant to cefixime, but no re-
sistance to ceftriaxone or spectinomycin was found. The
results of the present surveillance initiated in 2009 [28]
were also used to replace penicillin G with ceftriaxone
(1 g single dose intramuscularly) as the first-line drug
for empiric treatment of gonorrhoea in the national
treatment guidelines in Belarus in late 2009. Accord-
ingly, based on the present study and resistance data
from worldwide [2,5-11,19,30-33,40-42,45], ceftriaxone
should be the only option for first-line empiric anti-
microbial monotherapy of gonorrhoea in Belarus. Spec-
tinomycin should be the alternative treatment option
and only used when ceftriaxone is not available or the
patient suffers from a severe β-lactam allergy. However,
if pharyngeal gonorrhoea has not been excluded azithro-
mycin is recommended to be added to the spectino-
mycin regimen. It is essential to further strengthen the
surveillance of gonococcal AMR and ideally survey also
treatment failures and molecular epidemiological geno-
types in Belarus.
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